ClearPoint Neuro, Inc. (CLPT)
NASDAQ: CLPT · Real-Time Price · USD
11.97
-0.45 (-3.62%)
Mar 28, 2025, 4:00 PM EDT - Market closed
ClearPoint Neuro Revenue
In the year 2024, ClearPoint Neuro had annual revenue of $31.39M with 31.04% growth. ClearPoint Neuro had revenue of $7.77M in the quarter ending December 31, 2024, with 14.11% growth.
Revenue (ttm)
$31.39M
Revenue Growth
+31.04%
P/S Ratio
10.31
Revenue / Employee
$272,957
Employees
115
Market Cap
330.76M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 31.39M | 7.44M | 31.04% |
Dec 31, 2023 | 23.96M | 3.40M | 16.56% |
Dec 31, 2022 | 20.55M | 4.25M | 26.09% |
Dec 31, 2021 | 16.30M | 3.47M | 27.05% |
Dec 31, 2020 | 12.83M | 1.61M | 14.37% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCLPT News
- 4 weeks ago - ClearPoint Neuro: Drug Delivery Prospects Continue To Strengthen - Seeking Alpha
- 4 weeks ago - ClearPoint Neuro, Inc. (CLPT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results - Accesswire
- 6 weeks ago - ClearPoint Neuro to Announce Fourth Quarter and Full Year 2024 Results February 26, 2025 - Accesswire
- 6 weeks ago - ClearPoint Neuro Announces EU MDR Certification for the SmartFlow Cannula - Accesswire
- 2 months ago - ClearPoint Neuro Announces FDA Clearance for ClearPoint Navigation Software Version 3.0 - Accesswire
- 4 months ago - ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain - Accesswire
- 4 months ago - ClearPoint Neuro: Near-Term Volatility Is No Concern - Seeking Alpha